BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
08 juin 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
23 mai 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases...
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
10 mai 2023 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
09 mai 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
03 mai 2023 20h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
28 avr. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
04 avr. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
29 mars 2023 08h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
16 mars 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
06 mars 2023 07h00 HE
|
BioCardia, Inc.
New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart...